Study title: Open Label, Multicenter, Phase IIIB, Follow up Study to Investigate the Antibody Response to Hepatitis B, Acellular Pertussis and Inactivated Poliovirus Antigens one Month after the 4th Hexavac® Vaccination in Healthy Children, who Participated in the NeisVac-C Non-Interference Study 216
| Type of medicine: Non-centrally authorised vaccines | |||||
| Therapeutic area: Virus Diseases [C02]Â | |||||
| Brands: | |||||
| MAH holders: | |||||
| Assessment: | |||||
| Active substance: N. meningitidis group C polysaccharide conjugated to tetanus toxoid adsorbed on Al3+ | |||||
| ATC code: J07AH | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: Study 224 | |||||
| EudraCT number: | |||||
| Scope of study: CLINICAL | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |